Case presentation of XXXX combined with @entity356 with the longest survival record -- @entity8579 : pathophysiology, diagnosis and therapy.

@entity1 @entity5 @entity1066 @entity4773 @entity8579 @entity8243 @entity10042 @entity3 @entity356 @entity1943 @entity7581 @entity2275
BACKGROUND: @entity8579 is a very rare disease caused by @entity5 with @entity8243 producing cells accompanied by hypergastrinemia leading to @entity2275 . CASE STUDY: Female case of @entity7581 ( @entity8579 ; Z-E) with a record of 38 yrs of survival. Acute @entity4773 started at 28 yr of age and Z-E was diagnosed by using @entity8243 assays. Basal and maximal acid outputs and ratio of basal/maximal outputs were away over normal limits. Because of @entity1066 recurrence and complications, @entity1 was subjected to several gastric surgeries but refused total gastrectomy. She was also treated with many H2-receptor (R) antagonists and proton-pump inhibitors (PPI), each new drug being initially highly effective but then showing declining efficacy except when PPI, @entity10042 was used. The @entity8243 level rose in the course of disease from initial high value of 2000 pg/mL to the extreme 4500 ng/mL at present. During the last 2 yrs, @entity3 mainly to liver developed and they were successfully treated by synthetic octapeptide derivative of @entity1943 and, as a result, metastatis partly reduced and plasma @entity8243 drasticly decreased. Biopsy taken from liver @entity3 showed the presence of typical @entity7581 cells with @entity8243 and chromogranin, while that from oxyntic mucosa revealed the ECL-cell hyperplasia with @entity5 and unexpected @entity356 . CONCLUSIONS: This phenomenal case described in this article might be the new proven evidence needed by gastroenterologists to overturn the traditional treatment using total gastrectomy as a treatment of choice to the partial gastrectomy combined with proton pump inhibitors.
